The specter of generic competition has consistently loomed over copyright’s iconic drug, Sildenafil, triggering questions about the outlook of similar pharmaceutical portfolios. While early periods saw impressive gains, the patent expiration has created the door for less expensive substitutes, possibly diminishing profitability and posing a real